Mona Al-Ahmad is an expert in Immunology at Tzu Chi University (Taiwan). As of October 2026, ScienceLeadR ranks Mona Al-Ahmad in the top 1% of experts worldwide for Asthma, Hypersensitivity and Lung Diseases, Obstructive. Mona Al-Ahmad has authored 192 publications, the most recent in 2026, and is an investigator in 2 clinical trials. SLR score: 679 (community average: 125). How the SLR is computed.

LeadR Profile

Mona Al-Ahmad Tzu Chi University Taiwan
679 ScienceLeadR Reputation 679
Network Map

Immunology

Subspecialties: Pulmonology - Dermatology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2015 - 2026

Source: PubMed

Kuwait University

Publications Synthesis

Sources: PubMed, OpenAlex

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
World Allergy Organization Sublingual Immunotherapy Position Paper: 2026 update: Global expert consensus on efficacy, safety, disease modification, and implementation.
PMID 42835691 — safety, sublingual immunotherapy, hypersensitivity, duration of therapy, allergens, immunotherapy, therapeutics, allergy
World Allergy Organ J20261
Small airway dysfunction as a functional barrier to spirometry-defined clinical remission in severe asthma treated with biologic therapies.
PMID 42828135 — biomarkers, spirometry, therapeutics, asthma, biological therapy
World Allergy Organ J20260
Management of chronic urticaria: Current status and future prospect.
PMID 42712073 — chronic urticaria, sexually transmitted diseases, histamine antagonists, urticaria, skin diseases, biomarkers, precision medicine, diagnosis, therapeutics, angioedema, mast cells
J Eur Acad Dermatol Venereol20260
Budget impact analysis for albuterol-budesonide fixed-dose combination in the as needed treatment of adult patients with asthma in Kuwait.
PMID 42682159 — albuterol, pharmaceutical preparations, budgets, therapeutics, drug costs, asthma, budesonide
J Med Econ20260
Association of Easier Biologic Access with Remission and Other Clinical Outcomes in Severe Asthma: A Global Real-World Study.
PMID 42638984 — therapeutics, asthma
J Asthma Allergy20260

Clinical Studies 2

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 2

By status:

Active not recruiting 1
Completed 1

By type:

Observational 2

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 0
multicentricup10 2

Main Topics

LeadR Networks

Main global connection map